Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

Uy, Natalie; Nadeau, Michelle; Stahl, Maximilian; Zeidan, Amer M

Uy, Natalie; Nadeau, Michelle; Stahl, Maximilian; Zeidan, Amer M.

Afiliación

Uy N; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Nadeau M; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Stahl M; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

J Blood Med ; 9: 67-74, 2018.

Article en En | MEDLINE | ID: mdl-29713210

Palabras clave

CD22; acute lymphoblastic leukemia; antibody-drug conjugate; inotuzumab ozogamicin; monoclonal antibodies

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Blood Med Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google